Newsletter Tool

Today’s Big News

Aug 13, 2024

Rivus succeeds in obesity-related heart failure, posting phase 2 win for muscle-sparing molecule

In a one-two punch for Lykos, 3 articles on MDMA treatment retracted due to unethical conduct

Sluggish enrollment leads Boundless Bio to make 'modest' layoffs 5 months after $100M IPO

Eli Lilly unwraps $700M nucleic acid R&D center in Boston Seaport, opens doors to biotechs

Ovid halts preclinical work, IV seizure program in wake of soticlestat’s phase 3 stumble

Fierce Biotech Layoff Tracker 2024: Lexicon halves team; Boundless lets go of staffers

Featured

Rivus succeeds in obesity-related heart failure, posting phase 2 win for muscle-sparing molecule

By Nick Paul Taylor

Rivus Pharmaceuticals has plumped up the prospects of its fat busting, muscle sparing drug candidate, reporting a primary endpoint hit in a phase 2a trial of people with obesity-related heart failure.

In a one-two punch for Lykos, 3 articles on MDMA treatment retracted due to unethical conduct

By Gabrielle Masson

The journal Psychopharmacology has pulled three articles about several midstage clinical trials assessing Lykos Therapeutics’ investigational MDMA candidate for treating post-traumatic stress disorder. The journal cited “unethical conduct” at a research site as the reason for the retraction.

Sluggish enrollment leads Boundless Bio to make 'modest' layoffs 5 months after $100M IPO

By James Waldron

Only five months after securing a $100 million IPO, Boundless Bio is already laying off some employees as the precision oncology company grapples with low enrollment for a trial of its lead drug.

Eli Lilly unwraps $700M nucleic acid R&D center in Boston Seaport, opens doors to biotechs

By Nick Paul Taylor

Eli Lilly has opened a $700 million R&D center in the Boston Seaport, boosting its RNA and DNA research capabilities and expanding its biotech-hosting Gateway Labs to the East Coast for the first time.

Ovid halts preclinical work, IV seizure program in wake of soticlestat’s phase 3 stumble

By James Waldron

“Following Takeda's unexpected phase 3 results for soticlestat, we moved rapidly to focus our resources to preserve capital,” Ovid CEO Jeremy Levin said.

Fierce Biotech Layoff Tracker 2024: Boundless lets go of staffers; Lexicon halves team

By Gabrielle Masson,Darren Incorvaia,Max Bayer

We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs.

23andMe to launch GLP-1 telehealth offering, trims internal drug development team

By Heather Landi

23andMe plans to launch a GLP-1 weight loss telehealth membership through its Lemonaid Health platform by the end of the month.

After icodec rejection, Novo Nordisk plots 2024 FDA filing for once-weekly insulin and semaglutide combo

By Fraiser Kansteiner

Despite hitting a roadblock on the path to approval for its once-weekly insulin icodec in the United States, Novo Nordisk is continuing to move full speed ahead with a combo treatment pairing the drug with its unstoppable GLP-1 semaglutide.

KFF: A look at prior authorization trends in Medicare Advantage

By Paige Minemyer

Prior authorization denials in Medicare Advantage jumped between 2021 and 2022, according to a new analysis from KFF.

Fierce podcasts

Don’t miss an episode

What 'The Next Berlin Patient' and a PrEP’s 100% efficacy mean for HIV drug development

This week on “The Top Line,” we dive into two studies in HIV research that were presented at the 25th International AIDS Conference in Germany.

New mandatory bundled payment model for hospitals

Fierce 15: Where are they now?

Resources

Whitepaper

Launching a Product in Europe: Understanding Supply Chain Cost Drivers

This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs.

Efficient-Pro Medium and Feed 1 enable rapid and seamless upstream process development and scale-up for CHO-K1 cells

Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale.

2024 Life Sciences Industry Outlook

The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond.